StockNews.AI
BIIB
StockNews.AI
29 days

Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary

1. Biogen plans $2 billion investment in North Carolina manufacturing. 2. Total investment in RTP exceeds $10 billion since 1995. 3. Expansion includes antisense oligonucleotide capabilities and advanced automation. 4. Biogen's manufacturing supports over 1,900 skilled employees in North Carolina. 5. 90% of Biogen's commercial medicines are manufactured in the U.S.

10m saved
Insight
Article

FAQ

Why Bullish?

This significant investment demonstrates Biogen's confidence in its pipeline and market position. Aligning with historical trends, such investments have previously led to increased investor confidence and price appreciation.

How important is it?

The article underscores Biogen's strategic investment in core operations, which is crucial for its upcoming therapeutics. The robust commitment to R&D reflects positively on Biogen's competitive stance in the biotech sector.

Why Long Term?

The investment will enhance manufacturing capabilities over time, fostering growth in upcoming product launches. Similar past endeavors have helped Biogen maintain robust performance indicators, boosting long-term revenue.

Related Companies

AMGNREGNVRTXGILD
July 21, 2025 07:30 ET  | Source: Biogen Inc. Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the company’s pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline. In the next few years, Biogen plans to continue investing in multiple modalities and factories across the company’s two campuses in RTP. These investments will include further expansion of the antisense oligonucleotide (ASO) capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities, and continuing to modernize manufacturing technologies and controls through further advanced automation and artificial intelligence. “We are proud of our longstanding commitment to manufacturing innovation, investment, and collaboration with the Research Triangle Park community,” said Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen. “Our manufacturing footprint in the United States has played a critical role in Biogen’s history and success, and in advancing the treatments that are making an impact for patients, families, and communities here in the U.S. and around the world. With this investment, we will modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.” North Carolina’s RTP is home to Biogen's largest manufacturing footprint. As the state's largest biotechnology employer and one of the top five biopharmaceutical employers, Biogen employs over 1,500 manufacturing and technical employees and more than 400 skilled contractors across its Wake County and Durham County campuses. More than 90% of innovator commercial medicines produced by Biogen have manufacturing and quality control testing in the U.S. About Biogen’s global manufacturing footprint Biogen’s overall global manufacturing supply chain strategy aims at ensuring resilient and high-quality patient supply through robust risk management including geographical risk diversification and dual sourcing. In the United States, the Research Triangle Park (RTP) area in North Carolina is the home for Biogen’s largest manufacturing facilities. Our manufacturing operations in North Carolina include seven manufacturing factories across multiple modalities. An eighth state-of-the-art factory is currently under construction and will be operational in the second half of 2025. In addition to state-of-the-art manufacturing, our North Carolina campuses include sophisticated quality control laboratories to ensure the safety, efficacy, and purity of the medicines we produce. More than 90% of innovator commercial medicines produced by Biogen have manufacturing and quality control testing in the U.S. Outside the United States, Biogen has a smaller manufacturing footprint which supplies certain international markets. In Europe, the company operates one biologics factory in Switzerland and is consolidating certain ex-U.S. fill finish capabilities in Europe into one site in Ireland. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, including about the anticipated benefits of new investments in Biogen’s global manufacturing footprint; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Related News